Olema Pharmaceuticals (OLMA) Insider Graham Buys 29,500 Shares

Graham Walmsley, an insider at OLMA, purchased 29,500 shares of the company on June 18, 2026. This transaction wasn't part of a pre-planned trading scheme.

Insider Buying and Selling at Olema Pharmaceuticals, Inc.

Alongside Graham Walmsley, other insiders including Sandra Horning, Yi Larson, Andrew Rappaport, Gorjan Hrustanovic, and Ian Clark each bought 29,500 shares of OLMA on the same day. These transactions were also not conducted under pre-planned trading arrangements.

Other Institutional Activity in OLMA

Several institutional investors adjusted their holdings in OLMA recently. FMR LLC significantly increased its stake, adding 5,363,753 shares to hold a total of 10,386,845 shares valued at about $154.9 million, marking a 106.8% increase. Paradigm Biocapital Advisors LP also grew its position by 476,404 shares, ending with 8,020,576 shares worth $119.6 million, a 6.3% increase. Meanwhile, Bain Capital Life Sciences Investors, LLC reduced its holdings by 1,035,403 shares, now holding 7,473,238 shares valued at $111.4 million, which is a 12.2% decrease. Janus Henderson Group PLC and BlackRock, Inc. both increased their stakes slightly, with Janus Henderson adding 398,294 shares and BlackRock adding 88,875 shares.

Olema Pharmaceuticals, Inc. Stock Up 7.2%

On Wednesday, OLMA's shares traded near $10.00. The stock's recent performance includes a 52-week low and high, with significant institutional interest reflected in the recent trades.

Analysts Set New Price Targets

Several analysts have maintained a positive outlook on OLMA. On May 13, 2026, Guggenheim maintained its buy rating with a price target of $35.00. Jefferies assumes a buy rating with a $40.00 target as of March 19, 2026. JP Morgan also maintained a buy rating with a higher target of $58.00 on March 18, 2026. Other firms like Goldman Sachs, Citigroup, and HC Wainwright & Co. have set targets ranging from $27.00 to $62.00, all maintaining buy ratings.

Bottom Line

Graham Walmsley's purchase of OLMA shares signals confidence in the company's future. The recent insider buying, along with significant institutional activity, suggests that many see potential in OLMA. Analysts are also optimistic, with several maintaining high price targets. Investors often track such insider and institutional moves as they can provide insights into the company's prospects.